Cytocom, Inc. Announces Plan to Adopt New Corporate Name “Statera BioPharma, Inc.”

Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced plans to change its corporate name to “Statera BioPharma, Inc.” and update its ticker symbol to “STAB” effective Wednesday, September 1, 2021. As part of the name change, Statera BioPharma (NASDAQ: STAB) plans to release a new company logo and launch a new company website at The new corporate name, Statera, taken from the Latin word for “balance,” and tagline “Restoring Immune Health” was chosen to better reflect the company’s strategic focus on addressing autoimmune and inflammatory diseases, blood disorders, infectious disease and cancer.

Cytocom, Inc. emerged as a publicly-traded entity following the merger between the former Cleveland BioLabs and the formerly private Cytocom Inc., completed on July 27, 2021.

“The new corporate name, Statera BioPharma and updated ticker symbol mark the latest event in a transformative year for the company,” said Michael K. Handley, President and CEO of Cytocom. “The completion of the recent merger transaction brought together two companies and promising technology platforms to create a potential powerhouse in the immune modulation field with one of the largest pipelines of toll-like immune receptors in the biopharmaceuticals industry. Our new name emphasizes the work underway as we advance our late-stage clinical assets that are designed to restore immune health.”

Find out more in the press release.

Categories: Ecosystem News